
Annual report 2025
added 04-15-2026
Vivos Therapeutics Net Debt 2011-2026 | VVOS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Vivos Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -888 K | -4.58 M | 31 K | -1.11 M | -22.5 M | -16.9 M | 3.24 M | -568 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.24 M | -22.5 M | -5.41 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
-925 M | $ 191.66 | 0.84 % | $ 14.4 B | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.67 | 0.08 % | $ 1.71 B | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.42 | -2.01 % | $ 128 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 60.99 | -5.03 % | $ 90.3 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.65 | -2.26 % | $ 40.5 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 11.16 | -5.34 % | $ 316 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 25.4 | -2.53 % | $ 215 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.05 | -0.94 % | $ 17.8 M | ||
|
Globus Medical
GMED
|
-511 M | $ 96.82 | 1.65 % | $ 13.1 B | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 5.49 | 0.73 % | $ 1.16 B | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.12 | - | $ 1.29 M | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 10.88 | 0.18 % | $ 390 M | ||
|
LivaNova PLC
LIVN
|
-282 M | $ 65.81 | -1.95 % | $ 3.59 B | ||
|
Inogen
INGN
|
-86.3 M | $ 6.95 | 1.91 % | $ 185 M | ||
|
Inspire Medical Systems
INSP
|
-433 M | $ 56.97 | -1.08 % | $ 1.67 B | ||
|
CONMED Corporation
CNMD
|
802 M | $ 39.68 | 1.54 % | $ 1.23 B | ||
|
Integer Holdings Corporation
ITGR
|
1.18 B | $ 89.32 | -0.98 % | $ 3.1 B | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 16.65 | -0.6 % | $ 391 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.8 | - | $ 123 M | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 81.44 | 0.56 % | $ 47.6 B | ||
|
LENSAR
LNSR
|
-10.2 M | $ 5.55 | -6.41 % | $ 66.4 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Myomo
MYO
|
-4.79 M | $ 0.9 | 4.73 % | $ 37.7 M | ||
|
Smith & Nephew plc
SNN
|
1.5 B | $ 34.21 | -0.44 % | $ 23.8 B |